KPKorean Society Of Cardio-Cerebrovascular Disease Prevention
Korean Society Of Cardio-Cerebrovascular Disease Prevention
Background: Cardiovascular disease (CVD) is the second most common cause of death in Korea. We investigated the incidence rate of CVD in the Korean adult population using the Korean National Health Insurance Service database.Methods: This cohort included individuals aged 20 years and older who participated in the National Health Screening Program in 2012, and longitudinal follow-up data were collected through December 2022. The incidence of CVD, myocardial infarction, ischemic stroke, and cardiovascular mortality was evaluated. The incidence of CVD in relation to key cardiovascular risk factors was also analyzed.Results: A total of 4,737,616 participants were included in the final analysis. The mean age was 47.9 years, with a slight male predominance (54.1%). Older age, male sex, and current smoking were consistently associated with higher risk across all CVD outcomes. The overall adjusted incidence rate was 288.9 per 100,000 person-years for CVD. The 1.6-fold higher incidence of CVD in individuals with type 2 diabetes mellitus, 1.5-fold higher incidence in those with hypertension, and 1.4-fold in those with metabolic syndrome clearly demonstrate the cumulative risk conferred by these comorbidities. The most pronounced increase in cardiovascular mortality was observed in individuals with chronic kidney disease, reaching a 2.0-fold higher rate.Conclusions: CVD and its comorbidities in the Korean adult population represent a significant health burden. Prompt and aggressive lifestyle modification and management of risk factors should be actively emphasized.
Background/Objectives: Cardiac implantable electronic devices (CIEDs) can prevent ventricular arrhythmia-related sudden cardiac death but cause paradoxical discomfort that impairs daily living and quality of life. No management guidelines exist for reducing pain, improving motion around the CIED implantation site, or preventing shoulder contractures. We evaluated the impact of continuous successive shoulder rehabilitation programs for CIED patients on reducing shoulder pain, improving shoulder range of motion, and patient satisfaction in daily living. Methods: In this prospective observational study, patients who had received CIED implantation underwent shoulder rehabilitation therapy with education during hospitalization from the day post-CIED implantation. After in-hospital rehabilitation, patients chose to undergo successive shoulder rehabilitation from their home and after 4 weeks in the outpatient clinic (rehabilitation group, n = 68) or not (non-rehabilitation group, n = 33). Pain and shoulder function was assessed using the Visual Analog Scale (VAS) and Disability of the Arm, Shoulder, and Hand (DASH) scores, respectively, the day following CIED implantation and at 1–3 months postoperatively. Patient satisfaction was evaluated using the 36-item Short Form Survey (SF-36). Outcomes were compared between groups. Results: VAS pain scores significantly decreased, while DASH scores substantially improved in the rehabilitation group compared to the non-rehabilitation group. Although the SF-36 subdomains were similar between groups, the rehabilitation group showed a better health-related quality of life trend. No complications were observed following post-CIED rehabilitation. Conclusions: Shoulder rehabilitation therapy with successive education after CIED implantation significantly improved pain and shoulder function. Definitive guidelines and long-term outcomes should be investigated further.
Background and Objectives: Chronic kidney disease (CKD) is associated with severe coronary calcification and increased procedural risks. We aimed to evaluate the impact of CKD on contrast-induced nephropathy (CIN), bleeding, and clinical outcomes in patients undergoing rotational atherectomy (RA). Materials and Methods: This study retrospectively analyzed 652 patients who underwent RA for calcified coronary lesions from the multicenter ROCK registry and a single-center extension between 2010 and 2025. Patients were classified into CKD (eGFR < 60 mL/min/1.73 m2, n = 66) and non-CKD (n = 586) groups, excluding those on dialysis. The primary endpoint was a composite of CIN and in-hospital bleeding. Secondary endpoints included 3-year target vessel failure (TVF), myocardial infarction (MI), and total bleeding. Results: The primary composite outcome occurred more frequently in the CKD group (16.7% vs. 5.1%, p = 0.001). Specifically, CIN was significantly higher in CKD patients (15.2% vs. 1.7%, p < 0.001), while in-hospital bleeding did not differ significantly. In multivariate analysis, CKD was an independent predictor of the primary outcome (adjusted OR 3.02; 95% CI 1.36–6.69; p = 0.006). At 3-year follow-up, total bleeding (10.6% vs. 3.9%, p = 0.008) and MI (6.1% vs. 2.1%, p = 0.024) were higher in the CKD group, whereas TVF and cardiac death showed no significant difference. Conclusions: CKD is a robust independent risk factor for CIN and long-term bleeding in patients undergoing RA. However, comparable clinical efficacy outcomes suggest that RA remains a feasible strategy in CKD patients when early complications are carefully managed with contrast-minimizing strategies.
18 June 2026 in American Journal of Preventive Cardiology
(1) Background: Atrial fibrillation (AF) is the most common arrhythmia and poses a clinical dilemma in the very elderly due to increased thromboembolic and bleeding risks. This study aimed to evaluate clinical outcomes—including thromboembolic events, major bleeding, and all-cause mortality—by age group in elderly East Asian patients with non-valvular AF receiving oral anticoagulants. (2) Methods: This retrospective single-center study included 502 patients aged ≥70 years treated with direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, edoxaban, or apixaban) or warfarin between 2016 and 2024. Patients were stratified into two age groups: 70–79 and ≥80 years. The primary outcomes were ischemic stroke, systemic thromboembolism, and major bleeding. (3) Results: Although patients aged ≥80 years showed a numerically higher incidence of bleeding in both the DOAC and warfarin groups, these differences were not statistically significant after multivariable adjustment (DOAC group: HR 0.832; 95% CI, 0.456–1.518; p = 0.549; warfarin group: HR 3.617; 95% CI, 0.600–21.804; p = 0.161). Ischemic and thromboembolic event rates were also comparable between age groups. (4) Conclusions: Despite a numerically higher bleeding risk in the very elderly, DOACs remained safe and effective when appropriately managed. These findings support individualized anticoagulation decisions based on clinical factors rather than age alone in elderly East Asian patients with AF.